Cell Source

About:

Cell Source focuses on developing cell therapy treatments based on the management of immune tolerance.

Website: http://cell-source.com

Description:

Cell Source is a biotechnology company focused on developing cell therapy treatments based on the management of immune tolerance. The company’s patented "Veto-Cell" technology represents a major breakthrough in immune system management - safe and selective “tolerizing” of immune response. Cell Source’s technology addresses one of the most fundamental challenges in human immunology: how to tune immune response so that it tolerates specific “desirable” foreign cells while continuing to attack all other potential threats. Cell Source is currently commercializing this groundbreaking innovation. Potential applications range from facilitating bone marrow and organ transplantation to effectively treating both blood cancers (e.g., Lymphoma) and non-malignant congenital diseases (e.g., Sickle Cell Anemia).

Total Funding Amount:

$9.53M

Estimated Revenue Range:

$10M to $50M

Headquarters Location:

New York, New York, United States

Founded Date:

2011-01-01

Founders:

Yoram Drucker

Number of Employees:

1-10

Last Funding Date:

2019-10-18

IPO Status:

Public

Industries:

© 2025 bioDAO.ai